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The regulatory role between ischemia related factors and antimicrobial peptides in congenital intra-abdominal adhesions has not
yet been defined.The aim of this research was to investigate the appearance and relative distribution of VEGF, HBD-2, and HGF in
congenital intra-abdominal adhesions comparedwith relatively healthy tissue controls.The study groupmaterialwas obtained from
48patientswho underwent abdominal surgery due to partial or complete bowel obstruction. VEGF,HBD-2, andHGFwere detected
using immunohistochemistry methods and their relative distribution was evaluated by means of the semiquantitative counting
method. The results were analyzed using nonparametric statistic methods. A moderate number of VEGF positive endotheliocytes
were detected, but therewas no statistically significant difference between the groups. In the experimental group, amoderate to high
number of VEGF positive macrophages was observed. In control group tissues, such macrophages were seen in significantly lower
number (U = 61.0, p = 0.001).The increase of VEGF positive cells indicates support of angiogenesis due to the hypoxic conditions in
case of adhesion disease. The number of HBD-2 marked fibroblasts and macrophages was moderate to high, but only few positive
endotheliocytes were observed. Persisting appearance of HBD-2 positive structures might be a result of the inflammatory process.
Most specimens showed occasional HGF positive macrophages and fibroblasts and there was no statistically significant difference
between the groups. The relatively weak appearance of HGF suggests that the lack of this factor promotes the formation of fibrotic
changes in case of intra-abdominal adhesions.
1. Introduction
Peritoneal adhesions are defined as pathological fibrotic
bands that develop between any surfaces in the peritoneal
cavity [1]. Depending on the etiology, peritoneal adhesions
may be classified as congenital or acquired, of which themost
frequent are postinflammatory or postoperative adhesions
[2].
The pathogenesis of adhesion formation involves three
important processes: (I) inhibition of the fibrinolytic and
extracellular matrix degradation systems, (II) induction
of an inflammatory response involving the production of
cytokines and transforming growth factor-𝛽 (TGF-𝛽), and
(III) induction of tissue hypoxia, leading to increased expres-
sion of vascular endothelial growth factor (VEGF) [2].There-
fore, the aim was to research appearance of ischemia related
factors and antimicrobial peptides in the tissue of congenital
adhesions.
VEGF was first described by Senger et al. in 1983 as
a tumor secreted “vascular permeability factor” [3]. It was
originally identified as an endothelial cell specific growth
factor stimulating angiogenesis [4]. In addition to endothelial
cells, VEGF and VEGF receptors are expressed on numer-
ous nonendothelial cells including macrophages, platelets,
mesotheliocytes, and fibroblasts [5–7]. Macrophages play a
key role in the induction of angiogenesis in fibroproliferative
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states [6]. Macrophage production of VEGF is increased
under hypoxic conditions [5]. Fibroblasts may store VEGF
in a latent state for urgent use in angiogenesis [8]. VEGF is
upregulated in the postoperative adhesion formation [9].
Human beta-defensin-2 (HBD-2) could link inflamma-
tion and the host defense through its proangiogenic activity
[10]. HBD-2 is cysteine-rich antimicrobial peptide of the
human innate immune system with a broad antibacterial
spectrum and rare bacterial resistance [11]. HBD-2 usually
exhibits a stronger potential antimicrobial activity against
gram-negative organisms [12]. HBD-2 may also enhance the
inflammatory response since it is a specific chemoattractant
for human neutrophils [13]. HBD-2 was originally described
in psoriatic lesions and it is produced following stimulation of
epithelial cells by contact with microorganisms or cytokines
such as TNF-alpha and IL-1 [14]. HBD-2 is the main defensin
present in the peritoneal membrane [15].
Hepatocyte growth factor (HGF), also named “hepa-
totropin,” is a heterodimer molecule composed of a 69
kDa alpha-subunit and a 34 kDa beta-subunit [16]. HGF is
expressed in a wide variety of cells, including endothelial
cells, macrophages, and fibroblasts [17, 18]. HGF targets
vascular endothelial cells and is a potent angiogenic factor
[19]. It stimulates proliferation and migration of various cell
types via tyrosine phosphorylation of the HGF receptor, c-
Met [20]. Mesothelial cell proliferation andmigration play an
important role in reducing formation of postoperative peri-
toneal adhesions [21]. HGF prevents peritoneal thickening
and inhibits expression of TGF-𝛽1 and type 1 collagen in rat
peritoneum [22]. HGF strongly exerts intestinal adhesions
by diminishing interferon-gamma (IFN-𝛾) production [23].
HGF has been reported to prevent the fibrosis within the
peritoneum that is associated with enhanced peritoneal cell
proliferation and viability [24].
The aim of this research was therefore to investigate
the appearance and relative distribution of VEGF, HBD-2,
and HGF in specimens of patients with congenital intra-
abdominal adhesions.
2. Materials and Methods
The study was approved by the university ethics committee
and was performed according to the principles of the Decla-
ration of Helsinki.
The material was obtained from 48 patients (22 males, 26
females) who underwent abdominal surgery due to complete
or partial bowel obstruction. 19 out of 48 specimens were
evaluated as congenital adhesions (embryonic peritoneal
adhesions, Ladd band), but 29 were evaluated as acquired
adhesions related to gastrointestinal perforation, diffuse peri-
tonitis, and repeated surgeries.
Most frequently adhesions were localized between the
jejunal small intestinal loops and the proximal parts of ileum
(20 cases) or at the duodenal region (ten cases). In four cases
specimens were obtained from the distal parts of the ileum.
In 12 cases adhesions were forming a Ladd band, but in
another two cases the anterior abdominal wall was involved
(see Table 1).
The control group was obtained from eight patients (six
males, two females) with surgical repair of inguinal hernia
(see Table 2). All patients were under one year of age.
The tissue material was fixed in Stefanini solution [25].
After fixation the study material was dehydrated, using
alcohol solutions from 70∘ till 96∘, and degreased in xylene
solution. Then tissues were embedded in paraffin and the
blocks of paraffinized tissues were sectioned into slides 3-4
𝜇m in thickness by means of a microtome (Leica RM2245,
Leica Biosystems Richmond Inc., USA). To acquire an
overview morphologic picture, the slides were processed for
hematoxylin and eosin. Stained preparations were analyzed
by light microscope (Leica DM500RB, Leica Biosystems
Richmond Inc., USA).
3. Immunohistochemical Analysis
Tissue immunohistochemical staining for biomarkers identi-
fication was done by biotin-streptavidin method [26], using
the following VEGF (code-orb191500, rabbit, polyclonal,
working dilution 1:100, Biorbyt Ltd., United Kingdom),HBD-
2 (code-sc-20798, rabbit, polyclonal, working dilution 1:100,
Santa Cruz Biotechnology, Inc., USA), and HGF (code-AF-
294-NA, goat, polyclonal, working dilution 1:300, R&D Sys-
tems, Germany) antibodies. All antibodies used in research
were diluted with Antibody Diluent (code-938B-05, Cell
Marque, USA).
Adhesion tissue cuts were deparaffinized and washed
in alcohol and water, then rinsed with TRIS buffer (code-
2017X12508, Diapath S.p.A., Italy) twice for 5 minutes, and
placed in boiling EDTA buffer (code-2017X02239, Diapath
S.p.A., Italy) in microwave for 5 minutes. When the samples
had cooled down, they were washed twice for 5 minutes in
TRIS wash buffer. Further, blocking for 10 minutes in 3%
peroxide solution was performed and then washed twice
for 5 minutes in TRIS wash buffer. To decrease background
staining, normal blocking serum for 20minutes was used. All
tissue samples were incubated with primary antibodies for 1
hour.
HiDef Detection HRP polymer system was used for
the rabbit origin antibodies. The specimens were incubated
for 10 minutes at room temperature with HiDef Detection
Amplifier (code-954D-31, Cell Marque, USA). Another
washing for 5 minutes in TRIS wash buffer was performed.
Further, incubation for 10 minutes at room temperature with
HiDef Detection HRP Polymer Detector (code-954D-32,
Cell Marque, USA) was performed. After this processing,
the preparations were rinsed for 5 minutes by TRIS buffer
solution. After rinsing, DAB substrate-chromogen system
(code-957D-60, CellMarque, USA)was used for 10minutes
to obtain positive structure staining in brown color.
For antibodies obtained from goat ImmunoCruz ABC
staining system (code-sc-2023; Santa Cruz Biotechnology,
Inc., USA) was used. After incubation of the specimens
with the primary antibody for 1 hour at room temperature,
rinsing three times for 5 minutes in TRIS buffer solution was
performed. Tissue cuts were incubated for 30 minutes with
biotin containing secondary antibody (biotinylated goat Ig).
Then repeated sample rinsing for 5 minutes in TRIS buffer
The Scientific World Journal 3
Table 1: Experimental group.
Age (days)/ Sex Location Age (days)/ Sex Location Age (days)/ Sex Location
1 0/M SI 17 4/F SI 33 56/M SI
2 0/F D 18 9/F D 34 56/F SI
3 0/F LB 19 9/F D 35 62/F D
4 1/M SI 20 9/F AAW 36 67/M SI
5 1/F LB 21 9/M LB 37 71/F SI
6 1/M SI 22 14/M SI 38 94/F SI
7 1/F LB 23 15/M LB 39 100/F SI
8 1/F D 24 19/F SI 40 103/M D
9 1/M AAW 25 26/F LB 41 108/M DI
10 2/M SI 26 28/M DI 42 129/M DI
11 2/M SI 27 30/F SI 43 130/F D
12 2/M D 28 36/F SI 44 134/F SI
13 2/M LB 29 39M D 45 151/F SI
14 3/M LB 30 41/F LB 46 185/F SI
15 4/M D 31 48/M LB 47 210/M DI
16 4/F LB 32 51/F LB 48 292/F SI
Abbreviations: M, male; F, female; SI, small intestine; DI, distal ileum; D, duodenum; LB, Ladd’s band; AAW, anterior abdominal wall.










Abbreviations: M, male; F, female.
solution followed for three times and after that incubation
with enzyme peroxidase bounded streptavidin for 30 min at
room temperature. Then again washing in TRIS wash buffer
for 5 minutes followed. Tissue coating with DAB substrate-
chromogen system and incubation at room temperature,
resulting in a positive structure coloring brown, was done for
up to 10 minutes.
Regardless of the staining system, after incubation with
chromogenic substrate system samples were rinsed in run-
ning water and counterstained with hematoxylin (code-05-
M06002, Mayer’s Hematoxylin, Bio Optica Milano S.p.A.,
Italy).
Finally, all samples were dehydrated in increasing con-
centration alcohols and clarified with carboxylic acid and
xylene, as well as covering with the glue Pertex (code-00811;
HistoLab, Sweden).
Slides were examined under the light microscope. Find-
ings were photographed with a Leica DC 300F camera and
analyzed with image-processing and analysis software Image
Pro Plus.
The semiquantitative counting method was used for
the registration of the relative amount of immunopositive
structures [27].The amount of structures was analyzed in five
fields of view (magnification X 250) in a randomly selected
section. The average amount of structures was chosen for
further analysis. The designations were as follows:
0: no positive structures in the visual field;
0/+: occasionally positive structures in the visual field;
+: few positive structures in the visual field;
+/++: few tomoderate positive structures in the visual
field;
++: moderate positive structures in the visual field;
++/+++: moderate to numerous positive structures in
the visual field;
+++/++++: numerous to abundant positive struc-
tures in the visual field;
++++: abundant positive structures in the visual field.
4. Data Analysis
To characterize the research group descriptive statistic meth-
ods were used. For the description of each marker, median
and interquartile range were used. Data analysis was con-
ducted using nonparametric statistical methods. Spearman’s
rank correlation coefficient (rs) was calculated to evaluate
correlation in between ischemia related factors and antimi-
crobial peptides. The acquired results were interpreted: rs ≤
0.3, weak correlation; 0.3< rs< 0.7,moderate correlation; rs≥
0.7, strong correlation. For the comparison of groups, Mann-
Whitney U test was used. Two-tailed p values of <0.05 were
considered as statistically significant. Statistical analysis was
conducted using Statistical Package for the Social Sciences
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Table 3: Semiquantitative evaluation of immunoreactive structures.
Experimental grouptb Control group U p
VEGF Median ++ ++ 124.0 0.089
IQR 0.5 0.5
HBD-2 Median ++/+++ ++/+++ 185.5 0.951
IQR 1.5 0.5
HGF Median 0/+ 0/+ to + 137.5 0.182
IQR 1.0 0.85
Abbreviations: VEGF, vascular endothelial growth factor; HBD-2, human beta-defensin-2; HGF, hepatocyte growth factor; IQR, interquartile range; U, Mann
Whitney U value. Quantification of structures: 0, no positive structures in the visual field; 0/+, occasionally positive structures in the visual field; +, few positive
structures in the visual field; +/++, few tomoderate positive structures in the visual field; ++,moderate positive structures in the visual field; ++/+++,moderate
to numerous positive structures in the visual field.
(SPSS) program version 23.0 (IBM Corp., Armonk, NY,
USA).
5. Results
In the histologic overview specimen of the control group that
was obtained during inguinal hernia repair, an overall normal
histologic finding was seen. In all of the eight specimens, flat
mesotheliocytes were found. In the submesothelial loose con-
nective tissues, collagen fibers, fibroblasts, and rare, diffusely
placed macrophages were seen. In two cases, a slight sclerosis
of the blood vessel walls and in one of the specimens also
angiogenesis without inflammatory changes were observed.
In the adhesion tissues round shaped mesotheliocytes
and fibroblasts of modified shape were observed. Dense
connective tissue bundles were placed chaotically and some-
times also large collagen fiber bundles without fibroblasts
were seen. In almost all specimens, tissues were infiltrated
by polymorphonuclear leukocytes and macrophages. In one
part of the patient’s specimen inflammatory cells were places
diffusely, in the other part, perivascularly, often around
sclerotized arterioles. In case of pronounced inflammation,
epithelioid cells were seen. In the overview specimen angio-
genesis and hyperemic vessels could be often seen.
In the experimental group, a moderate number of VEGF
positive structures were detected, but there was no statis-
tically significant difference between the groups in general
(U = 124.0, p = 0.089). In 18 specimens, the number of
marked structures was moderate to high (++/+++), in 20
specimens moderate (++), and in four specimens few to
moderate (+/++).Only six cases showed few (+) or occasional
(0/+) VEGF positive structures. A positive reaction for VEGF
was found in endotheliocytes, mesotheliocytes, fibroblasts,
and macrophages (Figure 1(a)). The control group tissues
showedmoderate (++) or few tomoderate (+/++) appearance
of VEGF positive cells (Figure 1(b)).
In the experimental group, moderate to high number of
VEGF positive macrophages was observed. In control group
tissues, such macrophages were seen in significantly lower
number (U = 61.0, p = 0.001).
A positive reaction for HBD-2 was observed in fibrob-
lasts, macrophages, endotheliocytes, and mesotheliocytes
(Figure 1(c)). In 15 cases, the number of marked cells was high
(+++), in 10 cases moderate to numerous (++/+++), and in
seven cases moderate (++), but in nine cases few to moderate
(+/++). Few (+) positive cells were found in six cases. In the
control group tissues, HBD-2 positive structures (Figure 1(d))
were found in moderate (++) or moderate to high (++/+++)
number and there was no statistically significant difference
between the groups (U = 185.5, p = 0.951).
In the experimental group, only few positive endothe-
liocytes were observed. In control group tissues, positive
endotheliocytes were seen in significantly higher counts for
HBD-2 (U = 50.0, p < 0.001).
In the experimental group, HGF positive macrophages
and fibroblasts were mostly seen in occasional (0/+) appear-
ance. 16 specimens did not contain any HGF positive struc-
tures. Few (+) fibroblasts and macrophages contained this
factor in ten specimens. Only in 5 cases few to moderate
(+/++) or moderate (++) numbers of these structures were
positive forHGF.Apositive reaction forHGFwas observed in
epithelioid cells (Figure 1(e)). In the control group,most spec-
imens also showed occasional HGF positive macrophages,
fibroblasts, and mesotheliocytes (Figure 1(f)) and there was
no statistically significant difference between the groups (U =
137.5, p = 0.182).
All semiquantitative results are summarized in Table 3.
Using Spearman’s correlation test positive correlations
were observed between the immunoreactive structures for
HBD-2 and HGF (rs = 0.443, p = 0.002) and HBD-2 and
VEGF (rs = 0.625, p < 0.001) as well as between HGF and
VEGF (rs = 0.302, p = 0.037).
6. Discussion
Hypoxia, resulting from tissue injury, appears to play a
role in the pathophysiology of wound healing and adhesion
formation [28]. VEGF as a key mediator of angiogenesis
is critical for vascular remodeling during tissue repair after
inflammation or injury [29]. The mesothelial and vascular
endothelial cells in the peritoneal blood vessels express
VEGF [1]. Human peritoneal mesothelial cells contribute
to the intraperitoneal production of VEGF, which may
augment angiogenesis in the peritoneal membrane [7]. In
addition to eliciting endothelial proliferation, VEGF also
induces increased vascular permeability [30]. In our study




Figure 1: Immunoreactive structures in congenital adhesions and control group. (a)ModerateVEGF positive endotheliocytes, macrophages,
and fibroblasts in congenital adhesions of a 48-day-old patient (VEGF IMH, x250). (b) Moderate VEGF positive endotheliocytes and
fibroblasts of a 76-day-old patient in control group (VEGF IMH, x250). (c) Moderate HBD-2 positive fibroblasts, macrophages, and
mesotheliocytes in congenital adhesions of a 151-day-old patient (HBD-2 IMH, x250). (d)ModerateHBD-2 positive fibroblasts, macrophages,
and endotheliocytes of a 76-day-old patient in control group (HBD-2 IMH, x250). (e) Moderate HGF positive macrophages and epithelioid
cells in congenital adhesions of a two-day-old patient (HGF IMH, x250). (f) Few HGF positive mesotheliocytes of a 53-day-old patient in
control group (HGF IMH, x250).
the relatively low amount of VEGF positive endotheliocytes
demonstrates that there was no pronounced hypoxia that
could have stimulated neoangiogenesis.
However, there is data supporting that VEGF is upregu-
lated in the process of adhesion development. It is considered
a critical cytokine in the development of adhesions [9]. The
upregulation of VEGF may be a compensatory mechanism
regulating angiogenesis in order to provide nutrients and
oxygen to the injured tissues [31]. Despite the lack of
statistically significant difference between our study groups,
predominantly moderate appearance of VEGF in the exper-
imental group specimen suggests that production of VEGF
may affect the development of congenital intra-abdominal
adhesions. Our study reveals a more pronounced number of
VEGF containing macrophages. Macrophage production of
VEGF is increased under hypoxic conditions [5]. However,
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the causative link between hypoxia and angiogenesis in case
of adhesion disease remains a speculation.
HBD-2 is an antimicrobial peptide upregulated during
infection and inflammation [32]. The inducible antimi-
crobial peptide HBD-2 stimulated by proinflammatory
cytokines and bacterial products is essential to antipathogen
responses of gut epithelial cells [33]. In addition to their
antimicrobial abilities, these peptides are potent media-
tors of inflammation with stimulatory effects on epithe-
lial and inflammatory cells, influencing cell proliferation,
cytokine/chemokine production, and chemotaxis. HBD-2
has been reported to be elevated in patients with chronic
inflammatory conditions [34]. Thus, our data of moderate
to numerous appearance of HBD-2 in congenital intra-
abdominal adhesions might be the result of an inflammatory
process.
HBD-2 might link inflammation and the host defense
through its proangiogenic activity. HBD-2 stimulates chemo-
taxis of human endothelial cells with an extent similar to
VEGF [10]. This might explain positive correlations between
the immunoreactive structures for HBD-2 and VEGF.
HGF is a pleiotropic cytokine that may promote VEGF
driven angiogenesis [35]. Induction of angiogenesis by HGF
supplementation resulted in reduced local hypoxia. VEGF
enhanced endothelial permeability and edema, whereas HGF
inhibited endothelial permeability [20]. Combining VEGF
with HGF can promote neovascularization [35]. Appearance
of HGF and VEGD in intra-abdominal adhesions showed
positive correlation and can be associated with vascular
remodeling during adhesion formation.
HGF elicits the regression of peritoneal fibrosis, in which
TGF-𝛽-induced myofibroblasts are critical for tissue scar-
ring [20]. HGF inhibits TGF-𝛽 production in cultures of
myofibroblasts and antagonizes the actions of TGF-𝛽, thus
preventing fibrosis [36]. Moreover, HGF inhibits platelet
derived growth factor overproliferation of myofibroblasts,
reduces connective tissue growth factor induced scarring,
and inhibits monocyte chemoattractant peptide-1 medi-
ated inflammation during the HGF-mediated attenuation
of fibrosis [20]. HGF strongly inhibits intestinal adhesion
by diminishing IFN-𝛾 production [23]. IFN-𝛾 is a key
molecule for abdominal adhesion formation after hepate-
ctomy in mice, acting via the reciprocal balance between
plasminogen activator inhibitor-1 and tissue plasminogen
activator, the pivotal factors in fibrinolytic activity. HGF
strongly inhibits adhesion formation by regulating IFN-𝛾 and
plasminogen activator inhibitor-1 [37]. Our study showed
relative weak appearance of HGF. Therefore, the lack of
this factor might support formation of congenital intra-
abdominal adhesions.
7. Conclusions
The increase of VEGF positive cells indicates support of
angiogenesis due to the hypoxic conditions in case of adhe-
sion disease.
Persisting appearance of HBD-2 positive structuresmight
be a result of the inflammatory process.
The relatively weak appearance of HGF suggests this as
possible fibrosis supporting factor in the pathogenesis of
intra-abdominal adhesions.
VEGF, HBD-2, and HGF are part of the repair mecha-
nisms in the peritoneum.
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